Sign in or create an account to add this stock to your watchlist.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and interventional pulmonology products, including PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Specialty Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of envenomations from the copperhead snake; Vistogard for the treatment of 5-fluorouracil toxicity; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup for hip joint replacement; and Lemtrada for treatment of multiple sclerosis. The company also manufactures and commercializes therapeutic ultrasound devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:BTG
CUSIPN/A
Phone+44-20-75750000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins15.50%
Return on Equity10.80%
Return on Assets8.07%
Miscellaneous
EmployeesN/A
Outstanding Shares386,400,000
BTG (LON:BTG) Frequently Asked Questions
What is BTG's stock symbol?
BTG trades on the London Stock Exchange (LON) under the ticker symbol "BTG."
How were BTG's earnings last quarter?
BTG plc (LON:BTG) posted its quarterly earnings results on Tuesday, May, 15th. The company reported $32.90 earnings per share for the quarter, beating the Zacks' consensus estimate of $29.80 by $3.10. BTG had a return on equity of 10.80% and a net margin of 15.50%. View BTG's Earnings History.
What price target have analysts set for BTG?
7 Wall Street analysts have issued 1-year target prices for BTG's shares. Their forecasts range from GBX 640 to GBX 900. On average, they anticipate BTG's share price to reach GBX 745.83 in the next year. View Analyst Ratings for BTG.
Who are some of BTG's key competitors?
Some companies that are related to BTG include ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), Abcam (ABC), MorphoSys (MOR), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH) and Starpharma (SPL).
Who are BTG's key executives?
BTG's management team includes the folowing people:
- Dr. Louise Makin, CEO & Exec. Director (Age 57)
- Mr. Duncan Kennedy, Chief Financial Officer
- Dr. Peter Stratford, Chief Technical Officer and Head of Innovation (Age 51)
- Dr. Melanie G. Lee, Chief Scientific Officer (Age 60)
- Mr. Andy Burrows, VP of Corp. and Investor Relations
Has BTG been receiving favorable news coverage?
News coverage about BTG stock has been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BTG earned a news impact score of 0.13 on Accern's scale. They also assigned media coverage about the company an impact score of 45.80 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of BTG?
Shares of BTG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is BTG's stock price today?
One share of BTG stock can currently be purchased for approximately GBX 520.
How big of a company is BTG?
BTG has a market capitalization of £2.64 billion.
How can I contact BTG?
BTG's mailing address is 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom. The company can be reached via phone at +44-20-75750000.
MarketBeat Community Rating for BTG (BTG)
MarketBeat's community ratings are surveys of what our community members think about BTG and other stocks. Vote "Outperform" if you believe BTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
BTG (LON:BTG) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for BTG in the last 12 months. Their average twelve-month price target is GBX 745.83The high price target for BTG is GBX 900 and the low price target for BTG is GBX 640. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.57 | 2.63 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 745.83 | GBX 761.14 | GBX 774.13 | GBX 771.63 |
BTG (LON:BTG) Consensus Price Target History
BTG (LON:BTG) Analyst Ratings History
Show:
(Data available from 6/17/2016 forward)
BTG (LON:BTG) Earnings History and Estimates Chart
BTG (LON BTG) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/15/2018 | Y 2018 | GBX 29.80 | GBX 32.90 | | | View | N/A |  |
| 11/14/2017 | S1 2018 | GBX 21 | GBX 21 | | £341.30 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
BTG (LON:BTG) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
BTG (LON BTG) Insider Trading and Institutional Ownership History
BTG (LON BTG) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/8/2018 | Duncan Kennedy | Insider | Sell | 2,652 | GBX 556 | £14,745.12 | | |
| 6/9/2017 | Rolf Soderstrom | Insider | Sell | 22,624 | GBX 649 | £146,829.76 | | |
| 6/1/2017 | Rolf Soderstrom | Insider | Sell | 129,514 | GBX 655 | £848,316.70 | | |
| 7/21/2016 | Soderstrom,Rolf | Insider | Sell | 74,327 | GBX 676 | £502,450.52 | | |
| 7/6/2016 | Makin,Dame Pamela Louise | Insider | Sell | 256,404 | GBX 695 | £1,782,007.80 | | |
| 6/3/2015 | Rolf Soderstrom | Insider | Sell | 35,225 | GBX 704.88 | £248,293.98 | | |
(Data available from 1/1/2013 forward)
BTG (LON BTG) News Headlines
| Source: |
|
BTG (LON:BTG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
BTG (LON BTG) Stock Chart for Sunday, June, 17, 2018
Loading chart…
